Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note released on Friday. The firm issued a sell rating on the biopharmaceutical company’s stock.

A number of other brokerages also recently issued reports on MRNS. Royal Bank of Canada reduced their price target on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a report on Friday, October 25th. Truist Financial downgraded Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. JMP Securities reiterated a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday, October 24th. HC Wainwright reiterated a “neutral” rating and set a $2.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Finally, TD Cowen reiterated a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Marinus Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Stock Performance

Shares of NASDAQ:MRNS opened at $0.55 on Friday. Marinus Pharmaceuticals has a 1 year low of $0.22 and a 1 year high of $10.50. The stock’s 50-day moving average is $0.45 and its 200 day moving average is $0.89.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC lifted its position in Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 12,934 shares in the last quarter. World Investment Advisors LLC bought a new position in shares of Marinus Pharmaceuticals during the 3rd quarter valued at $104,000. Virtu Financial LLC bought a new position in shares of Marinus Pharmaceuticals during the 4th quarter valued at $36,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in shares of Marinus Pharmaceuticals during the 4th quarter valued at $54,000. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in shares of Marinus Pharmaceuticals by 39.5% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock valued at $729,000 after buying an additional 117,255 shares during the period. 98.80% of the stock is owned by institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.